JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Mark D RussellChristopher StovinEdward AlveynOlukemi AdeyemiChun Kit David ChanVishit PatelMaryam A AdasFabiola AtzeniKenrick K H NgAndrew I RutherfordSam NortonAndrew P CopeJames B GallowayPublished in: Annals of the rheumatic diseases (2023)
CRD42022362630.
Keyphrases